HEALTHEURACTIV
Biosimilars reshape immunology care across EU a decade after market entry [Advocacy Lab]
Biosimilars have expanded access to biologic therapies for millions of patients in the EU ten years after the first etanercept biosimilar entered the market.
Mentioned
Related Signal
Adjacent reporting
- UCB to acquire maker of antibody treatments for autoimmune diseases
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
- Long-lived immune cells show promise against cancer in world-first trial
- How a pill approved 25 years ago transformed cancer treatment
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
- How a pill approved 25 years ago transformed cancer treatment